Hematology Reports (Jun 2022)

CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy

  • Mustafa Nissar Bankur,
  • Archie Keeling,
  • Khoodoruth Mohamed Adil Shah,
  • Daniele Avenoso

DOI
https://doi.org/10.3390/hematolrep14030029
Journal volume & issue
Vol. 14, no. 3
pp. 213 – 221

Abstract

Read online

Herein, we present a case of cytomegalovirus (CMV) colitis that occurred after two cycles of azacitidine and venetoclax in a 64-year-old woman affected with acute myeloid leukaemia (AML) secondary to a previous diagnosis of a hypoplastic myelodysplastic syndrome (hypo-MDS). This patient never had detectable CMV viraemia, and there was no evidence of immune deficiency that could justify this opportunistic infection. Additionally, this is most likely the first report describing CMV colitis in a patient treated upfront with azacitidine and venetoclax.

Keywords